Notch is developing renewable, stem cell-derived immunotherapies, with an initial focus on cancer. We believe that cell therapies can bring value to patients and healthcare systems by being safe, effective, and accessible. Built on foundational discoveries in developmental immunology and enabled by world-class bioengineering and advanced cell manufacturing teams, Notch has developed a proprietary platform with the potential to fully enable best-in-class commercial manufacturing of stem-cell derived immunotherapies that bypass the need to use a patient’s own immune cells. The Notch Engineered Thymic Niche (ETN) provides developing hematopoietic cells the right signals at the right time to predictably direct their development. By mimicking the niche of the human thymus, precursor cells differentiate through a series of stable intermediate populations and emerge as fully functional immune cells. The process greatly simplifies manufacturing and has the potential to produce immune cells at scale without the use of any animal components or feeder cell lines. Applying our proprietary suite of gene editing and synthetic biology technologies to control stem cell division and differentiation, alter the tumor microenvironment, and enhance tumor antigen specificity and immune susceptibility, Notch is focused on developing a robust pipeline of next-generation cellular immunotherapies designed to offer transformational benefits over the existing standard of care.